Advances in treating HER2-positive breast cancer: an interview with Sunil Verma

In this podcast, we talk to Dr Sunil Verma about the evolution of HER2 as a therapeutic target in breast cancer, and about how targeted therapy has revolutionized breast cancer treatment. We also discuss new agents in clinical development and the ways in which advances in treating HER2-positive brea...

Descripción completa

Detalles Bibliográficos
Autor principal: Verma, Sunil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Question and Answer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244053/
https://www.ncbi.nlm.nih.gov/pubmed/25285580
http://dx.doi.org/10.1186/s12916-014-0129-y
_version_ 1782346177422819328
author Verma, Sunil
author_facet Verma, Sunil
author_sort Verma, Sunil
collection PubMed
description In this podcast, we talk to Dr Sunil Verma about the evolution of HER2 as a therapeutic target in breast cancer, and about how targeted therapy has revolutionized breast cancer treatment. We also discuss new agents in clinical development and the ways in which advances in treating HER2-positive breast cancer can be used to inform treatment decisions in other areas of medicine. The podcast for this interview is available at: http://media.biomedcentral.com/content/movies/supplementary/SunilVerma-QandA.mp3.
format Online
Article
Text
id pubmed-4244053
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42440532014-11-26 Advances in treating HER2-positive breast cancer: an interview with Sunil Verma Verma, Sunil BMC Med Question and Answer In this podcast, we talk to Dr Sunil Verma about the evolution of HER2 as a therapeutic target in breast cancer, and about how targeted therapy has revolutionized breast cancer treatment. We also discuss new agents in clinical development and the ways in which advances in treating HER2-positive breast cancer can be used to inform treatment decisions in other areas of medicine. The podcast for this interview is available at: http://media.biomedcentral.com/content/movies/supplementary/SunilVerma-QandA.mp3. BioMed Central 2014-08-12 /pmc/articles/PMC4244053/ /pubmed/25285580 http://dx.doi.org/10.1186/s12916-014-0129-y Text en © Verma; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Question and Answer
Verma, Sunil
Advances in treating HER2-positive breast cancer: an interview with Sunil Verma
title Advances in treating HER2-positive breast cancer: an interview with Sunil Verma
title_full Advances in treating HER2-positive breast cancer: an interview with Sunil Verma
title_fullStr Advances in treating HER2-positive breast cancer: an interview with Sunil Verma
title_full_unstemmed Advances in treating HER2-positive breast cancer: an interview with Sunil Verma
title_short Advances in treating HER2-positive breast cancer: an interview with Sunil Verma
title_sort advances in treating her2-positive breast cancer: an interview with sunil verma
topic Question and Answer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244053/
https://www.ncbi.nlm.nih.gov/pubmed/25285580
http://dx.doi.org/10.1186/s12916-014-0129-y
work_keys_str_mv AT vermasunil advancesintreatingher2positivebreastcanceraninterviewwithsunilverma

Ejemplares similares